Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Berry

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
PLOS Global Public Health|March 24, 2023
Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosisSedona Sweeney, Catherine Berry, Emil Kazounis, et al.
BMJ Open|September 7, 2021
Population pharmacokinetics and pharmacodynamics of investigational regimens' drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study): a prospective nested study protocol in a randomised controlled trialBern-Thomas Nyang'wa, Frank Kloprogge, David A J Moore, et al.
Journal of Biomaterials Applications|May 21, 2021
Engineering cartilage graft using mesenchymal stem cell laden polyacrylamide-galactoxyloglucan hydrogel for transplantationPreethi Gopalakrishnan Usha, Sreekutty Jalajakumari, Unnikrishnan Babukuttan Sheela, et al.
NPJ Vaccines|March 21, 2020
An optimized purified inactivated Zika vaccine provides sustained immunogenicity and protection in cynomolgus macaquesValérie Lecouturier, Vincent Pavot, Catherine Berry, et al.
NPJ Vaccines|December 8, 2025
Establishing long-lasting vaccine immunity: insights from mRNA and adjuvanted protein platformsAndrea-Clemencia Pineda-Peña, Kohei Hasegawa, Vincent Pavot, et al.
Vaccine|May 1, 2018
Characterization of recombinant yellow fever-dengue vaccine viruses with human monoclonal antibodies targeting key conformational epitopesValerie Lecouturier, Catherine Berry, Aure Saulnier, et al.
Nature Communications|June 10, 2026
Pharmacokinetics, bactericidal activity and toxicity of short oral regimens for rifampicin-resistant tuberculosis treatmentBern-Thomas Nyang'wa, Ilaria Motta, Ronelle Moodliar, et al.
PLOS Global Public Health|September 24, 2024
Prevalence, treatment, and outcomes of hepatitis C in an MDR/RR-TB trial cohortJocelyn Jansen van Vuuren, Tim Crocker-Buque, Catherine Berry, et al.
Emerging Infectious Diseases|October 22, 2015
Multidrug-Resistant Tuberculosis in Child Successfully Treated with 9-Month Drug RegimenJay Achar, Catherine Berry, Krzysztof Herboczek, et al.
Trials|June 13, 2022
TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosisCatherine Berry, Philipp du Cros, Katherine Fielding, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
PLOS Global Public Health|March 24, 2023
Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosisSedona Sweeney, Catherine Berry, Emil Kazounis, et al.
BMJ Open|September 7, 2021
Population pharmacokinetics and pharmacodynamics of investigational regimens' drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study): a prospective nested study protocol in a randomised controlled trialBern-Thomas Nyang'wa, Frank Kloprogge, David A J Moore, et al.
Journal of Biomaterials Applications|May 21, 2021
Engineering cartilage graft using mesenchymal stem cell laden polyacrylamide-galactoxyloglucan hydrogel for transplantationPreethi Gopalakrishnan Usha, Sreekutty Jalajakumari, Unnikrishnan Babukuttan Sheela, et al.
NPJ Vaccines|March 21, 2020
An optimized purified inactivated Zika vaccine provides sustained immunogenicity and protection in cynomolgus macaquesValérie Lecouturier, Vincent Pavot, Catherine Berry, et al.
NPJ Vaccines|December 8, 2025
Establishing long-lasting vaccine immunity: insights from mRNA and adjuvanted protein platformsAndrea-Clemencia Pineda-Peña, Kohei Hasegawa, Vincent Pavot, et al.
Vaccine|May 1, 2018
Characterization of recombinant yellow fever-dengue vaccine viruses with human monoclonal antibodies targeting key conformational epitopesValerie Lecouturier, Catherine Berry, Aure Saulnier, et al.
Nature Communications|June 10, 2026
Pharmacokinetics, bactericidal activity and toxicity of short oral regimens for rifampicin-resistant tuberculosis treatmentBern-Thomas Nyang'wa, Ilaria Motta, Ronelle Moodliar, et al.
PLOS Global Public Health|September 24, 2024
Prevalence, treatment, and outcomes of hepatitis C in an MDR/RR-TB trial cohortJocelyn Jansen van Vuuren, Tim Crocker-Buque, Catherine Berry, et al.
Emerging Infectious Diseases|October 22, 2015
Multidrug-Resistant Tuberculosis in Child Successfully Treated with 9-Month Drug RegimenJay Achar, Catherine Berry, Krzysztof Herboczek, et al.
Trials|June 13, 2022
TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosisCatherine Berry, Philipp du Cros, Katherine Fielding, et al.
Pageof 4